scholarly journals Corrigendum: Covalent Complex of DNA and Bacterial Topoisomerase: Implications in Antibacterial Drug Development

ChemMedChem ◽  
2021 ◽  
Author(s):  
Purushottam B. Tiwari ◽  
Prem P. Chapagain ◽  
Ahmed Seddek ◽  
Thirunavukkarasu Annamalai ◽  
Aykut Üren ◽  
...  
Keyword(s):  
Drug Development ◽  
Antibacterial Drug ◽  
Covalent Complex

scholarly journals Covalent Complex of DNA and Bacterial Topoisomerase: Implications in Antibacterial Drug Development

ChemMedChem ◽  
2020 ◽  
Vol 15 (7) ◽  
pp. 623-631
Author(s):  
Purushottam B. Tiwari ◽  
Prem P. Chapagain ◽  
Ahmed Seddek ◽  
Thirunavukkarasu Annamalai ◽  
Aykut Üren ◽  
...  
Keyword(s):  
Drug Development ◽  
Antibacterial Drug ◽  
Covalent Complex

Promoting Antibacterial Drug Development: Select Policies and Challenges

2016 ◽  
Vol 15 (1) ◽  
pp. 113-118 ◽  
Author(s):  
Aylin Sertkaya ◽  
Amber Jessup ◽  
Hui-Hsing Wong
Keyword(s):  
Drug Development ◽  
Antibacterial Drug

scholarly journals Antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase: pseudouridimycin

2017 ◽  
Author(s):  
Sonia I. Maffioli ◽  
Yu Zhang ◽  
David Degen ◽  
Thomas Carzaniga ◽  
Giancarlo Del Gatto ◽  
...  
Keyword(s):  
Antibacterial Activity ◽  
Drug Development ◽  
Rna Polymerase ◽  
Binding Site ◽  
Bacterial Pathogens ◽  
Nucleoside Analog ◽  
Cross Resistance ◽  
Nucleoside Triphosphate ◽  
Antibacterial Drug ◽  
Bacterial Rna

There is an urgent need for new antibacterial drugs effective against bacterial pathogens resistant to current drugs1–2. Nucleoside-analog inhibitors (NAIs) of viral nucleotide polymerases have had transformative impact in treatment of HIV3and HCV4. NAIs of bacterial RNA polymerase (RNAP) potentially could have major impact on treatment of bacterial infection, particularly because functional constraints on substitution of RNAP nucleoside triphosphate (NTP) binding sites4-5could limit resistance emergence4-5. Here we report the discovery, from microbial extract screening, of an NAI that inhibits bacterial RNAP and exhibits antibacterial activity against a broad spectrum of drug-sensitive and drug-resistant bacterial pathogens: pseudouridimycin (PUM). PUM is a novel microbial natural product consisting of a formamidinylated, N-hydroxylated Gly-Gln dipeptide conjugated to 6'-amino-pseudouridine. PUM potently and selectively inhibits bacterial RNAP in vitro, potently and selectively inhibits bacterial growth in culture, and potently clears infection in a mouse model ofStreptococcus pyogenesperitonitis. PUM inhibits RNAP through a binding site on RNAP (the "i+1" NTP binding site) and mechanism (competition with UTP for occupancy of the "i+1" NTP binding site) that differ from those of the RNAP inhibitor and current antibacterial drug rifampin (Rif). PUM exhibits additive antibacterial activity when co-administered with Rif, exhibits no cross-resistance with Rif, and exhibits a spontaneous resistance rate an order-of-magnitude lower than that of Rif. The results provide the first example of a selective NAI of bacterial RNAP, provide an advanced lead compound for antibacterial drug development, and provide structural information and synthetic routes that enable lead optimization for antibacterial drug development.

scholarly journals Structure-based Druggability Assessment of Anti-virulence Targets from Pseudomonas aeruginosa

2019 ◽  
Vol 20 (12) ◽  
pp. 1189-1203 ◽  
Author(s):  
Thamires Q. Froes ◽  
Regina L. Baldini ◽  
Sandor Vajda ◽  
Marcelo S. Castilho
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Drug Development ◽  
In Silico ◽  
Global Economy ◽  
Drug Targets ◽  
Attractive Alternative ◽  
Antibacterial Drug ◽  
Hotspot Analysis ◽  
Combined Use ◽  
Druggable Targets

Antimicrobial Resistance (AMR) represents a serious threat to health and the global economy. However, interest in antibacterial drug development has decreased substantially in recent decades. Meanwhile, anti-virulence drug development has emerged as an attractive alternative to fight AMR. Although several macromolecular targets have been explored for this goal, their druggability is a vital piece of information that has been overlooked. This review explores this subject by showing how structure- based freely available in silico tools, such as PockDrug and FTMap, might be useful for designing novel inhibitors of the pyocyanin biosynthesis pathway and improving the potency/selectivity of compounds that target the Pseudomonas aeruginosa quorum sensing mechanism. The information provided by hotspot analysis, along with binding site features, reveals novel druggable targets (PhzA and PhzS) that remain largely unexplored. However, it also highlights that in silico druggability prediction tools have several limitations that might be overcome in the near future. Meanwhile, anti-virulence drug targets should be assessed by complementary methods, such as the combined use of FTMap/PockDrug, once the consensus druggability classification reduces the risk of wasting resources on undruggable proteins.

Sign in / Sign up

Export Citation Format

Share Document